Tarsus Pharmaceuticals, Inc. (TARS) › Operating IncomeTarsus Pharmaceuticals, Inc. (TARS) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$4.30M2020: -$27.00M2021: -$12.16M2022: -$62.71M2023: -$143.16M2024: -$120.57M2025: -$70.97M-$70.97M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$70.97M+41.1%2024-$120.57M+15.8%2023-$143.16M-128.3%2022-$62.71M-415.9%2021-$12.16M+55.0%2020-$27.00M-528.2%2019-$4.30M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share